AstraZeneca's Lynparza Approved in EU for Ovarian Cancer Patients
18 December 2014 - 6:52PM
Dow Jones News
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) said Thursday the European
Commission has given permission for the company's drug Lynparza to
be marketed to some patients with ovarian cancer.
The drugs company said the commission, the European Union's
executive arm, has granted marketing authorization for Lynparza
capsules "as the first therapy for the maintenance treatment of
adult patients with platinum-sensitive relapsed BRCA (Breast
Cancer)-mutated (germline and/or somatic) high grade serous
epithelial ovarian, fallopian tube, or primary peritoneal cancer
who are in complete response or partial response to platinum-based
chemotherapy."
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024